-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Ambrx Biopharma Cayman, Inc. quarterly/annual Nonoperating Income (Expense) history and change rate from 2019 to Q2 2023.
- Ambrx Biopharma Cayman, Inc. Nonoperating Income (Expense) for the quarter ending 30 Jun 2023 was $1,649,000, a 2325% increase year-over-year.
- Ambrx Biopharma Cayman, Inc. annual Nonoperating Income (Expense) for 2022 was $342,000.
- Ambrx Biopharma Cayman, Inc. annual Nonoperating Income (Expense) for 2021 was $-3,863,000, a 18.2% increase from 2020.
- Ambrx Biopharma Cayman, Inc. annual Nonoperating Income (Expense) for 2020 was $-4,723,000, a 3108% decline from 2019.
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Change (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Change (%)